Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of $970.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mohit Bansal has given his Buy rating due to a combination of factors including Eli Lilly & Co’s robust financial guidance and strategic growth initiatives. The company’s projected earnings per share (EPS) for 2025 are aligned with investor expectations, providing a sense of stability and confidence. This guidance is supported by strong performance in specific segments such as Humalog and a one-time benefit from Jardiance, which helped achieve impressive quarterly revenue figures.
Additionally, Eli Lilly & Co’s future growth is expected to be driven by the international expansion of Mounjaro, momentum in newer drugs like Jaypirca and Ebglyss, and potential new product launches such as imlunestrant. These factors, combined with an expected increase in manufacturing capacity and improved market access, underpin the positive outlook for the company’s revenue and earnings growth, justifying a Buy rating.
In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $997.00 price target.